Turing Pharmaceuticals

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge. What Happened: On Saturday, in a post on X, Shkreli forecasted a potential 90% drop in the shares of biotech startup, Inmune Bio Inc. (NASDAQ:...

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge. What Happened: On Saturday, in a post on X, Shkreli forecasted a potential 90% drop in the shares of biotech startup, Inmune Bio Inc. (NASDAQ:...

Justice came for Martin Shkreli. The so-called “Pharma Bro” was sentenced Friday to 84 months in prison after having been convicted in August 2017 on two counts of securities fraud and one count of conspiracy to commit securities fraud. Prosecutors were looking for 15 years prison time...

After years of case-building, federal prosecutors will finally meet Martin Shkreli in court Monday, June 26, for a six-week trial. The former hedge-fund manager and pharmaceutical executive will face eight charges of securities and wire fraud, for which he has pleaded not guilty. “I’m...

Even under proverbial shackles, Martin Shkreli continues to flex his powerful muscles. The founder and former CEO of Turing Pharmaceuticals could reclaim corporate leadership ahead of the June 26 start to his securities fraud trial. The board of Turing met Wednesday and shareholders voted to elect...

Let’s talk Daraprim — again. The controversially pricey drug that set regulators on their toes and prompted critical evaluations of pharmaceutical practices nearly switched hands this week as Turing Pharmaceuticals considered a $100 million cash offer, according to Endpoints News....

Academy Award-winning actor Matthew McConaughey stars in the new movie “Gold,” which tells the story of fraudulent Canadian gold mining company Bre-X. Bre-X is only one of hundreds of crazy Wall Street characters and stories fit for the big screen. Here are four crazy Wall Street...

Following a report exposing Martin Shkreli as a whistleblower against Mallinckrodt PLC (NYSE: MNK), Shkreli told Benzinga that the Federal Trade Commission's new lawsuit is just. “Questcor [Mallinckrodt subsidiary] stopped me from competing with their very high-priced drug which made...

Pharmaceutical compounder Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) first stepped onto the national stage in December 2015, when the company announced its partnership with Express Scripts Holding Company (NASDAQ: ESRX) to distribute a $1 Daraprim alternative following Martin Shkreli and Turing...

Martin Shkreli put up his $45 million E*Trade Financial Corp (NASDAQ: ETFC)account to secure his $5 million bail, according to a filing released Thursday. The former biopharma executive was ordered to disclose how the $5 million bond was secured. "E*Trade has been ordered to notify...

While a company's financials may be one of the most important factors when it comes to making investment decisions, the person at the helm can make or break a firm's image in the public eye. This year, the private sector was full of scandals, crises and high-stakes decisions that cast the...

The most unpopular man in the pharmaceutical world is in a little bit of trouble. Turing Pharmaceuticals founder Martin Shkreli has been arrested on securities fraud related to a firm he founded, Bloomberg reported Thursday morning. Separately, Reuters citing witness said the entrepreneur...

Martin Shkreli, CEO of Turing Pharmaceuticals, controversially raised the price of a potentially life-saving drug called Daraprim to $750 a pill from $13.50. Express Scripts Holding Company (NASDAQ: ESRX), the largest manager of prescription drug benefits, said on it will now cover a $1 a...

Martin Shkreli, CEO of Turing Pharmaceuticals, hosted a Reddit "Ask Me Anything." Shkreli became "the most hated man on the Internet" after he acquired a drug called Daraprim and raised its price to $750 a pill from $13.50. The top thread featured a discussion with a confirmed doctor who "schooled...

The cover story in this weekend's Barron's focuses on banks helping clients care for aging parents. The Penta Quarterly includes a look at America's top 40 wealth management firms. The prospects for BorgWarner, Autodesk, Edgewell Personal Care, JetBlue Airways and more are also covered in feature...